CREB3L1 and neoplasm: There are several tumor suppressors other than CREB3L1 that could be silenced by ROR1, suggesting that targeting ROR1 and its downstream DNMT-mediated epigenetic modifications could provide a novel therapeutic strategy for TNBC.